Eevia Health Plc, ("Eevia" or "The Company"), announces that it has received sales orders from Ingredient Plus of Australia for supply of bilberry extract with minimum 36% anthocyanins. The sales value of these orders is c. SEK 3 million, which to be prepaid and delivered in Q3-21.
Eevia considers these orders to be repeat business with an expected value of c. SEK 7-9 million per year, based on forecast from the customer, with possible growth. The bilberry extract, which is sold under the Eevia tradename Feno-Myrtillus® Organic, is protected as a Proprietary Ingredient (PI) with the Therapeutic Goods Administration of Australia.
The end customer is an internationally recognized brand leader in the South-East Asian marketplace. The group has sales of c. USD 460 million and dietary supplements, including single herbs, vitamins, minerals, and specialty formulas sold under the Company's well recognized brands, in over 12 markets.
CEO Stein Ulve comments: "These sale orders consolidate our position as the preferred provider of high concentration and high-quality anthocyanin extracts from the wild harvested arctic bilberry, which are mainly harvested in Sweden and Finland. These are important orders for us because they are stable contributions to our order- and customer-base and hence, our ability to reach our financial targets of minimum annual turnover in 2024 of EUR 25 million with a gross margin at minimum 40%."
This disclosure contains information that EEVIA HEALTH PLC is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agencies of the contact person, on July 1, 2021.
For further information, please contact:
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, is a small, but fast-growing Finnish manufacturer of 100% organically certified plant extracts. The Company addresses significant health problems with bioactive compounds extracted from plant material from the pristine Finnish forests near the Arctic Circle. The extracts, which have scientifically documented health benefits, are sold B2B as ingredients to dietary supplements and food brands globally. The focus is on ingredients that protect human health prophylactically, reducing the risk of deteriorating health. The products are targeted against immune health, low-grade inflammation, eye and brain health problems and metabolic disorders. In its portfolio.
Most of its raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion. The safe and effective ingredients of high quality, such as high concentrate bilberry anthocyanin extracts and pine bark extracts, are certified organic. Eevia Health operates a modern green-chemistry production facility in Finland, located close to the raw materials. The short value-chain enables an environmentally friendly carbon footprint, competitive pricing, and transparency.
The increasing health awareness among consumers, combined with the increased focus on sustainable business models, constitute a strong and significant macro-trend, from which Eevia stands well equipped to capitalize.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.
Information about Ingredient Plus
Ingredients Plus is a leading and independent distributor in the Asia-Pacific Region. Ingredients Plus recently celebrated it's 15-year anniversary. From its Head Office in Sydney, Ingredient Plus has quickly expanded across Australasia, Southeast Asia, and Greater China.
Ingredient Plus has a focus on key strategic markets, such as Beauty and Personal Care, Health, Pharmaceutical and Nutrition, and Household Care. Ingredients Plus specialize in providing advanced & innovative ingredients. Representing more than 20 key global manufacturers and thousands of products, Ingredients Plus supplies customers with complete solutions through flexible, reliable, and one-stop-shop supply of raw materials.
To learn more, please visit: www.ingredientsplus.com.au
Eevia Health Plc ("Eevia" or "The Company") is welcoming Tuomas Jylhä as interim Chief Financial Officer. Gabriella Beni has decided to leave the Company for personal reasons to focus on private matters. Eevia wishes her the very best in her future endeavors. Tuomas Jylhä will take over the position on July 26th.
Analyst Group Initiates equity research Coverage of Eevia Health Plc, ("Eevia" or "The Company").
Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus.
Eevia Health Plc, ("Eevia" or "The Company"), has received a 21 KEUR sales order from its Australian distributor Ingredients Plus for a new product made from Lingonberry, after a new customer has decided to launch a new product with the Lingonberry ingredient as a key component.
Eevia Health Plc, ("Eevia" or "The Company"), has entered into an agreement whereby Exelity AB, Sweden will provide a credit line for Eevia of up to SEK 8 million, giving the Company increased working capital flexibility to finance its continued growth.
The Annual General Meeting of Shareholders of Eevia Health Plc, corp. reg. no 2825194-4 (the "Company") was held on June 21, 2022 in Seinäjoki, Finland, whereby the shareholders primarily resolved the following matters:
Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus. Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high-quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its products across Asia and Oceania.
The shareholders of Eevia Health Abp, company registration number 2825194-4 in Finland, are hereby called for the Annual General Meeting (AGM) to be held on June 21st 2022.
Eevia Health Plc's (''Eevia'' or ''the Company'') Financial Statements for 2021 together with the Auditors' report have been published today.